A joint project of the European Group for Blood and Marrow Transplantation (EBMT) and the European Mantle Cell Lymphoma Network (EMCL) has produced a consensus report on the role of autologous and allogeneic HCT in MCL. Recommendations for use of autologous HCT include: auto HCT should be the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; and complete or partial remission should be achieved before autologous HCT. Recommendations in support of allogeneic HCT include: allogeneic HCT should be considered for patients relapsing after autologous HCT; reduced intensity conditioning regimens should be used; and allogeneic immunotherapy should be used for minimal residual disease eradication after allogeneic HCT.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Consensus Report: The Role of Autologous and Allogeneic HCT in MCL
Sep 2014